IBEC and Vitala, a spin-off founded by IBEC researchers, are set to participate in three public-private partnership projects, with a combined investment nearing €4 million. These initiatives, backed by the Spanish Ministry of Science and Innovation and the State Research Agency, aim to advance remote health monitoring, create an oral drug for Inflammatory Bowel Disease, and enhance 13C magnetic resonance imaging for therapeutic research. Leveraging cutting-edge technological approaches, these endeavors aspire to make a positive impact on the fields of medicine and biomedical research.
For the sixth consecutive year, IBEC has successfully hosted its ‘Mad for Bioengineering’ course with the support of the Catalunya La Pedrera Foundation. Geared towards 1st-year high school students interested in STEM careers, the program provides a unique immersion in the field of bioengineering, addressing health issues from a multidisciplinary perspective. The closing ceremony, attended by students and their families, featured presentations of final projects and the awarding of diplomas.
The NanoBio&Med 2023 International Conference, held last week at the Barcelona Science Park (PCB) from November 21 to 23, has marked a milestone by presenting the latest developments in the … Read more
The researcher at the Institute for Bioengineering of Catalonia has been awarded an ERC Consolidator Grant. This prestigious European funding supports excellent scientists and scholars who are consolidating their independent research teams to pursue their most promising scientific ideas. The €2 million grant over 5 years will allow Bolognesi and her team to develop a new method for identifying mutations that lead to the formation of amyloids—aggregates of proteins that contribute to a variety of diseases, including Alzheimer’s and Parkinson’s.
The IBEC is set to lead the coordination of the PHOTOTHERAPORT project, which will be developed with funding from the European Innovation Council’s Pathfinder Open programme. The project focuses on the development of luminescent implants and light-activated drugs for innovative neuromodulation therapies. PHOTOTHERAPORT will comprise an international consortium of 8 institutions and will receive €3 million over 3 years for the preclinical study of these implants.